The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Findings From the RELEVANCE Trial in Follicular Lymphoma

Andre Goy, MD
Published Online:2:55 PM, Wed November 28, 2018



Andre Goy, MD, chairman and director, chief of lymphoma, and director of clinical and translational cancer research at John Theurer Cancer Center, discusses data from the RELEVANCE trial, which randomized patients with follicular lymphoma in need of therapy to receive either rituximab (Rituxan) plus lenalidomide (Revlimid) or a physician’s choice of bendamustine and rituximab plus CHOP or R-CHOP.

The results indicated no difference in terms of response, progression-free survival, and overall survival. There was also a similar rate of secondary and primary malignancies, according to Goy. This is still an issue since these patients had not received chemotherapy before.

Moving forward, Goy says that it is something to keep an eye on as it could potentially be a good option for patients who cannot receive chemotherapy. However, Goy does not suggest abandoning chemotherapy altogether. More research is necessary.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.